ATXS
Price
$7.39
Change
-$0.04 (-0.54%)
Updated
Sep 15, 04:59 PM (EDT)
Capitalization
415.93M
57 days until earnings call
CABA
Price
$1.91
Change
+$0.07 (+3.80%)
Updated
Sep 15, 04:59 PM (EDT)
Capitalization
174.7M
58 days until earnings call
Interact to see
Advertisement

ATXS vs CABA

Header iconATXS vs CABA Comparison
Open Charts ATXS vs CABABanner chart's image
Astria Therapeutics
Price$7.39
Change-$0.04 (-0.54%)
Volume$7.52K
Capitalization415.93M
Cabaletta Bio
Price$1.91
Change+$0.07 (+3.80%)
Volume$34.6K
Capitalization174.7M
ATXS vs CABA Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CABA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. CABA commentary
Sep 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and CABA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 16, 2025
Stock price -- (ATXS: $7.37 vs. CABA: $1.91)
Brand notoriety: ATXS and CABA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 165% vs. CABA: 178%
Market capitalization -- ATXS: $415.93M vs. CABA: $174.7M
ATXS [@Biotechnology] is valued at $415.93M. CABA’s [@Biotechnology] market capitalization is $174.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.82B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileCABA’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • CABA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATXS and CABA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 6 TA indicator(s) are bullish while CABA’s TA Score has 6 bullish TA indicator(s).

  • ATXS’s TA Score: 6 bullish, 4 bearish.
  • CABA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both ATXS and CABA are a good buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а -0.81% price change this week, while CABA (@Biotechnology) price change was +13.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.37%. For the same industry, the average monthly price growth was +6.67%, and the average quarterly price growth was +33.69%.

Reported Earning Dates

ATXS is expected to report earnings on Nov 12, 2025.

CABA is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+2.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($416M) has a higher market cap than CABA($175M). ATXS YTD gains are higher at: -17.562 vs. CABA (-18.943). ATXS has higher annual earnings (EBITDA): -131.42M vs. CABA (-140.83M). ATXS has more cash in the bank: 259M vs. CABA (195M). ATXS has less debt than CABA: ATXS (4.77M) vs CABA (24.9M). ATXS (0) and CABA (0) have equivalent revenues.
ATXSCABAATXS / CABA
Capitalization416M175M238%
EBITDA-131.42M-140.83M93%
Gain YTD-17.562-18.94393%
P/E RatioN/AN/A-
Revenue00-
Total Cash259M195M133%
Total Debt4.77M24.9M19%
FUNDAMENTALS RATINGS
ATXS vs CABA: Fundamental Ratings
ATXS
CABA
OUTLOOK RATING
1..100
3135
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4862
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CABA's Valuation (15) in the null industry is somewhat better than the same rating for ATXS (56) in the Biotechnology industry. This means that CABA’s stock grew somewhat faster than ATXS’s over the last 12 months.

CABA's Profit vs Risk Rating (100) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that CABA’s stock grew similarly to ATXS’s over the last 12 months.

CABA's SMR Rating (98) in the null industry is in the same range as ATXS (98) in the Biotechnology industry. This means that CABA’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's Price Growth Rating (48) in the Biotechnology industry is in the same range as CABA (62) in the null industry. This means that ATXS’s stock grew similarly to CABA’s over the last 12 months.

ATXS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CABA (100) in the null industry. This means that ATXS’s stock grew similarly to CABA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSCABA
RSI
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
89%
Momentum
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
82%
MACD
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
88%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 4 days ago
87%
Declines
ODDS (%)
Bearish Trend 28 days ago
90%
Bearish Trend 7 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CABA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CGEMY29.050.38
+1.33%
Capgemini SE
SNTL5.820.04
+0.61%
Sentinel Holdings Ltd.
NRTZF11.18N/A
N/A
Noritz Corp.
CCHI0.17N/A
N/A
Cambridge Capital Holdings, Inc.
PMOIF3.09N/A
N/A
Harbour Energy Plc

CABA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABA has been loosely correlated with IPSC. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then IPSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
+1.66%
IPSC - CABA
52%
Loosely correlated
-3.38%
ARWR - CABA
47%
Loosely correlated
N/A
GBIO - CABA
46%
Loosely correlated
-1.33%
PYXS - CABA
45%
Loosely correlated
-2.15%
KYTX - CABA
45%
Loosely correlated
-5.54%
More